Bristol-Myers Squibb Company Stock

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-18 pm EDT After market 07:12:47 pm
42.39 USD -1.76% Intraday chart for Bristol-Myers Squibb Company 42.56 +0.41%
Sales 2024 * 46.08B Sales 2025 * 46.02B Capitalization 87.47B
Net income 2024 * -5.41B Net income 2025 * 10.21B EV / Sales 2024 * 2.75 x
Net Debt 2024 * 39.18B Net Debt 2025 * 31.92B EV / Sales 2025 * 2.59 x
P/E ratio 2024 *
-15.9 x
P/E ratio 2025 *
8.34 x
Employees 34,100
Yield 2024 *
5.58%
Yield 2025 *
5.86%
Free-Float 69.27%
More Fundamentals * Estimated data
Dynamic Chart
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative MT
Earnings reports take center stage as tech stocks tumble Our Logo
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $45 From $67 MT
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly... Our Logo
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained MT
Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 MT
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
More news
1 day-1.76%
1 week+4.02%
Current month+2.07%
1 month+3.87%
3 months-12.24%
6 months-15.37%
Current year-17.38%
More quotes
1 week
39.93
Extreme 39.925
44.24
1 month
39.35
Extreme 39.35
44.24
Current year
39.35
Extreme 39.35
55.04
1 year
39.35
Extreme 39.35
65.38
3 years
39.35
Extreme 39.35
81.44
5 years
39.35
Extreme 39.35
81.44
10 years
39.35
Extreme 39.35
81.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 15-01-31
Director of Finance/CFO 55 19-11-19
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 19-11-19
Director/Board Member 59 16-03-31
Director/Board Member 59 20-08-31
More insiders
Date Price Change Volume
24-07-18 42.39 -1.76% 19,432,661
24-07-17 43.15 +4.73% 18,639,241
24-07-16 41.2 +2.62% 13,739,604
24-07-15 40.15 -0.77% 17,858,084
24-07-12 40.46 -0.71% 16,677,463

Delayed Quote Nyse, July 18, 2024 at 04:00 pm EDT

More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
43.15 USD
Average target price
51.69 USD
Spread / Average Target
+19.80%
Consensus